GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Valuation Rank

iX Biopharma (SGX:42C) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

iX Biopharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Valuation Rank
Comparable Companies
SGX:BFK ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
Website
https://www.ixbiopharma.com
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.